title: Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
abstract: Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.
authors.affiliation: Laboratorio de Epidemiología Molecular de Enfermedades Infecciosas, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. mmunoz.hgugm@salud.madrid.org
authors.forename: Salvador
authors.initials: S
authors.lastname: Resino
authors.forename: Claudia
authors.initials: C
authors.lastname: Palladino
authors.forename: Raquel
authors.initials: R
authors.lastname: Lorente
authors.forename: Dariela
authors.initials: D
authors.lastname: Micheloud
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Bellón
authors.forename: Beatriz
authors.initials: B
authors.lastname: Larru
authors.forename: Maria Dolores Gurbindo
authors.initials: MD
authors.lastname: Gutiérrez
authors.forename: Maria Isabel
authors.initials: MI
authors.lastname: de José
authors.forename: Rosa
authors.initials: R
authors.lastname: Polo
authors.forename: Maria Angeles
authors.initials: MA
authors.lastname: Muñoz-Fernández
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D020738:Leptin / Q000097:blood*; D061466:Lopinavir; D011446:Prospective Studies; D011744:Pyrimidinones / Q000009:adverse effects* / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D020738:Leptin; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir